Analysts See $-0.57 EPS for Sarepta Therapeutics, Inc. (SRPT)

June 15, 2018 - By Kurt Siggers

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 0.97 in 2018 Q1. Its down 0.25, from 1.22 in 2017Q4. It turned negative, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.
Sphera Funds Ltd has 2.8% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 248,997 shares. Moreover, Qs Investors Ltd Limited Liability Company has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 2,664 shares. Parametric Associate Limited Liability stated it has 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 43,767 are owned by J Goldman And Co Limited Partnership. Sigma Planning owns 22,300 shares. Legal & General Grp Inc Public Ltd Co holds 25,080 shares or 0% of its portfolio. Ny State Common Retirement Fund stated it has 72,570 shares or 0.01% of all its holdings. Utd Services Automobile Association holds 9,454 shares. Riggs Asset Managment Co reported 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Crow Point Ptnrs Ltd Liability Company owns 572 shares. Dupont Capital Mngmt owns 5,663 shares. State Of Wisconsin Invest Board has 59,000 shares for 0.01% of their portfolio. Lord Abbett Co Ltd Liability Co reported 397,852 shares. State Board Of Administration Of Florida Retirement Systems holds 0.01% or 34,033 shares. Tourbillon Cap Prtn L P has invested 2.23% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.57 EPS on July, 18.They anticipate $0.58 EPS change or 50.43 % from last quarter’s $-1.15 EPS. After having $-0.44 EPS previously, Sarepta Therapeutics, Inc.’s analysts see 29.55 % EPS growth. The stock increased 2.08% or $2.01 during the last trading session, reaching $98.78. About 1.65M shares traded or 32.02% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 15, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 16 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 14 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Sarepta Therapeutics had 27 analyst reports since January 3, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Monday, March 12 by Piper Jaffray. The rating was downgraded by Oppenheimer on Thursday, May 3 to “Hold”. The rating was maintained by Leerink Swann on Tuesday, May 15 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $92 target in Monday, March 12 report. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Overweight” rating given on Wednesday, February 21 by JP Morgan. Barclays Capital upgraded the shares of SRPT in report on Friday, May 11 to “Overweight” rating. Nomura maintained the stock with “Buy” rating in Tuesday, June 5 report. The company was downgraded on Wednesday, March 21 by Morgan Stanley. Credit Suisse maintained the stock with “Outperform” rating in Friday, May 4 report. Piper Jaffray maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Friday, February 9. Piper Jaffray has “Buy” rating and $60.0 target.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.47 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Nasdaq.com which released: “Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene …” on June 13, 2018, also Nasdaq.com with their article: “Sarepta Therapeutics to Present at Two Upcoming Investor Conferences” published on June 05, 2018, Nasdaq.com published: “3 Stocks That Tripled in Just 12 Months” on June 04, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Nasdaq.com and their article: “Biotech ETFs Are the Best Way to Play the Recovering Sector” published on May 30, 2018 as well as Streetinsider.com‘s news article titled: “Sarepta Therapeutics (SRPT) Announces Long-term Strategic Manufacturing Partnership with Brammer Bio” with publication date: June 13, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.